IMPORTANCE There are limited comparative data on the durability of neutralizing antibody (nAb) responses elicited by messenger RNA (mRNA) vaccines against the SARS-CoV-2 variants of concern (VOCs) in immunocompromised patients and healthy controls.

OBJECTIVE To assess the humoral responses after vaccination with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccines.

DESIGN, SETTING, AND PARTICIPANTS In this prospective, longitudinal monocentric comparative effectiveness study conducted at the Lausanne University Hospital, binding IgG anti-spike antibody and nAb levels were measured at 1 week, 1 month, 3 months, and 6 months after vaccination with mRNA-1273 (24.6% of participants) or BNT162b2 (75.3% of participants).

INTERVENTIONS All participants received 2 doses of either mRNA-1273 or BNT162b2 vaccines 4 to 6 weeks apart.

MAIN OUTCOMES AND MEASURES The primary outcome of the study was the persistence of nAb responses against the original, nonvariant SARS-CoV-2 (2019-nCoV) and different VOCs at 6 months after vaccination. Key secondary outcomes were associations of the type of mRNA vaccine, the underlying disease, and the treatment with the response to vaccination.

RESULTS Among the 841 participants enrolled between January 14 and August 8, 2021, the patient population comprised 637 participants (mean [SD] age, 61.8 [13.7] years; 386 [60.6%] female), and the healthy control population comprised 204 participants (mean [SD] age, 45.9 [12.0] years; 144 [70.6%] female). There were 399 patients with solid cancers, 101 with hematologic cancers, 38 with solid organ transplants, 99 with autoimmune diseases, and 204 healthy controls. More than 15,000 nAb determinations were performed against the original, nonvariant 2019-nCoV and the Alpha, Beta, Gamma, and Delta variants. The proportions of nAbs and their titers decreased in all study groups at 6 months after vaccination, with the greatest decreases for the Beta and Delta variants. For Beta, the proportion decreased to a median (SE) of 39.2% (5.5%) in those with hematologic cancers, 44.8% (2.7%) in those with solid cancers, 23.1% (8.3%) in those with solid organ transplants, and 22.7% (4.8%) in those with autoimmune diseases compared with 52.1% (4.2%) in healthy controls. For Delta, the proportions decreased to 41.8% (5.6%) in participants with hematologic cancer, 51.9% (2.7%) in those with solid cancers, 26.9% (8.7%) in those with solid organ transplants, and 30.7% (5.3%) in those with autoimmune diseases compared with 56.9% (4.1%) healthy controls. Neutralizing antibody titers decreased 3.5- to 5-fold between month 1 and month 6, and the estimated duration of response was greater and more durable among those participants vaccinated with mRNA-1273. In participants with solid cancers, the estimated duration of nAbs against the Beta variant was 221 days with mRNA-1273 and 146 days with BNT162b2, and against the Delta variant, it was 226 days with mRNA-1273 and 161 days with BNT162b2. The estimated duration of nAbs in participants with hematologic cancers was 113 and 127 days against Beta and Delta variants, respectively.

CONCLUSIONS AND RELEVANCE This comparative effectiveness study suggests that approximately half of patients with hematologic cancers and solid cancers, about 70% of patients with solid organ transplants or autoimmune diseases, and 40% of healthy controls have lost nAbs against the circulating VOCs at 6 months after vaccination. These findings may be helpful for developing the best boosting vaccination schedule especially in immunocompromised patients.
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Methods
Study Design and Population
Between January 14 and August 8, 2021, participants were enrolled in the ImmunoVax study, a single-center, prospective, longitudinal comparative effectiveness study of immunocompromised patients with solid cancers, hematologic cancers, autoimmune diseases, or solid organ transplants and healthy controls who received 2 doses of mRNA COVID-19 vaccines. All participants gave written informed consent. All participants with positive serological test results indicative of past SARS-CoV-2 infection at baseline were excluded from the immunologic analyses. Laboratory personnel were blinded to the origin of samples (study group and time of the collection). The study was approved by the institutional review board of the Lausanne University Hospital and is registered with the local ethics committee. This study follows the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) reporting guideline.34

Serologic Assays and Procedures
Participants received 2 doses of BNT162b2 or mRNA-1273 (Moderna) administered intramuscularly 19 to 131 days apart (mean [SD] 31.8 [7.0] days) or a single dose if participants had had a previous SARS-CoV-2 infection (12 participants). Binding IgG anti-S and anti-nucleocapsid antibody and nAb levels were determined using 2 Luminex (Luminex Corp)-based assays recently developed in our laboratory.35,36

Outcomes
The co-primary outcomes were seroconversion, as shown by the detection of binding IgG anti-S antibodies, and nAb responses against the VOCS in the study groups after vaccination with BNT162b2 or mRNA-1273 vaccine. The secondary outcome was safety after each vaccine dose, measured according to adverse events.

Statistical Analysis
Spike–angiotensin-converting enzyme 2 half maximal inhibitory concentration (IC_{50}) dilution values and binding IgG anti-S antibody ratios were log_{10} transformed for visualization and statistical modeling. Differences in anti-S nAbs IC_{50} dilution values and binding IgG anti-S antibody ratios between groups (ie, study groups or vaccine type) were tested using linear regression models for individual time points (at 1 month and 3 months after the second dose of vaccine) and adjusting for age (<60 or ≥60 years) and sex. When comparing responses across time points, a mixed effects model with a subject random effect was used instead. Resulting P values were adjusted for multiple testing using the Benjamini-Hochberg false discovery rate. Tests were 2-tailed, with an adjusted P < .05 considered statistically significant. The proportions of individuals with nAbs (anti-S nAbs IC_{50} dilution values ≤0) were calculated by taking into account patients scored as IgG negative (IgG anti-S antibody ratio values <5.19 U/mL) for which no neutralization
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

Original Investigation Research

May 2022 Volume 8, Number 5

Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

John A. O’Driscoll, GI, MS; Euel K. Thompson, MD, PhD; Tousif Ahmed, MBBS; William Marquart, MD; Lauren Schier, MD; Michelle Putnam, MBBS; Bradley K. Janowicz, MD; Liberty S. South, MLS; Linda DalBello-Hauser, MD; Sarah J. O’Connor, MA; Daniel C. Martin, MA; Euthymia D. Adams, MD; Brian R. Smith, MD; Jennifer A. Siler, MA; Robyn P. Yee, MSc; Mark E. Epstein, MD; Shafqat A. Khan, MD; Leslie M. Indyk, MD; Turkey A. Woon; Michael L. Cuthbertson, MD; Karen R. Hawes, MD;pa nS pe eN M V T in  S U:Supplement. Further details of the statistical analysis are found in eMethods in the Supplement.

Results

A total of 887 participants were enrolled in this prospective longitudinal comparative effectiveness study. After exclusions (43 patients withdrew from the study, and 3 could not be analyzed), the patient population comprised 637 participants (mean [SD] age, 61.8 [13.7] years [range, 19.4-92.5 years]; 386 [60.6%] female and 251 [39.4%] male; The healthy control population comprised 204 participants (mean [SD] age, 45.9 [12.0] years [range, 23.4-85.5 years]; 144 [70.6%] female and 60 [29.4%] male) (eFigure 1 in the Supplement). Information on the different treatments is provided in eTable 2 in the Supplement. Among the 637 patients, 399 patients (62.6%) were diagnosed with solid cancers, 101 patients (15.9%) had hematologic cancers, 99 patients (15.5%) had autoimmunity diseases, 38 patients (6.0%) received solid organ transplants. Three hundred and ninety-one patients (61.4%) were undergoing active systemic treatment at the time of vaccination: 200 patients (31.4%) with solid cancers, 57 (8.9%) with hematologic cancer, 96 (15.1%) with autoimmunee diseases, and 38 (6.0%) with solid organ transplants. The pathological conditions and treatments are detailed in eTables 1 and 2 in the Supplement.

Blood samples were collected at baseline before the first vaccine dose (visit 1) and at 1 week (visit 2), 1 month (visit 3), 3 months (visit 4), and 6 months (visit 5) after vaccination. Among the 841 active participants, 54 participants (12 healthy controls, 6 with solid organ transplants, 7 with hematologic cancer, 7 with autoimmune diseases, and 22 with solid cancers) having a positive serologic test result for binding IgG antibodies at visit 1, indicative of prior and/or ongoing SARS-CoV-2 infection, remained in the study but were excluded from the immunologic analyses. A total of 631 patients (75.3%) received BNT162b2, and 207 (24.6%) received mRNA-1273; information for 3 participants was unknown (eTable 1 in the Supplement). Five participants (0.6%: 2 healthy controls, 2 with autoimmune diseases, and 1 with solid cancer) were diagnosed with SARS-CoV-2 infection during the study. The interim results of the humoral response for participants up to visit 5 are reported in the present study, including data obtained up to December 18, 2021. At the time of analysis, 772 participants were included for immunologic analyses; For binding IgG anti-S antibodies (eFigure 2A in the Supplement). The median (SE) percentages were lower among the participants with solid organ transplants (65.5% [8.8%]), autoimmune diseases (81.8% [1.0%]), and treated hematologic cancers (86.0% [0.49%]). Of note, the levels of binding IgG anti-S antibodies were significantly lower in the participants with solid organ transplants (median, 81.1 U/mL; 95% CI, 1.9-527.9 U/mL), autoimmune diseases (median, 1623.9 U/mL; 95% CI, 882.1-2309.7 U/mL), and treated hematologic cancers (median, 1383.0 U/mL; 95% CI, 582.7-2224.2 U/mL) compared with the healthy controls (median, 1900.4 U/mL; 95% CI, 1816.1-2119.8) (P < .001 for all) (eFigure 2B in the Supplement), whereas the levels were not significantly different between the mRNA-1273 and BNT162b2 vaccines (eFigure 2C in the Supplement).

We next determined the nAb responses to vaccination against SARS-CoV-2 and the Alpha, Beta, Gamma, and Delta variants using a cell- and virus-free assay recently developed in our laboratory cross-validated with the criterion standard live virus assay. Almost the totality of healthy controls had nAbs against SARS-CoV-2 and the different variants (ranging from a median [SE] of 95.7% [1.49%] to 100% [0%]) (eFigure 3 in the Supplement) at 1 month after vaccination. The median (SE) proportions of responders at 1 month after vaccination were slightly lower in participants with untreated (range, 84.9% [2.73%]-98.3% [0.99%]) and treated solid cancers (range, 80.1%
Neutralizing antibody responses were measured against SARS-CoV-2 (the original, nonvariant SARS-CoV-2) and the different variants of concern. Data are expressed as IC₅₀ (half maximal inhibitory concentration) dilutions. Negative (gray bars) indicates IC₅₀ titers <50 dilutions; positive (colored bars) indicates IC₅₀ titers >50 dilutions. Values are median (SE, denoted by whiskers).

For example, at 1 month after vaccination, the IC₅₀ titers against SARS-CoV-2 were significantly lower in participants with solid organ transplants, autoimmune diseases, treated hematologic cancer, and untreated solid cancers compared with the other groups.

We subsequently evaluated the magnitude of the nAb responses as measured by IC₅₀ dilutions greater than 50, the cutoff for a positive diagnostic test result. At 1 month and 3 months after vaccination, the IC₅₀ titers against SARS-CoV-2 were significantly lower in participants with solid organ transplants, autoimmune diseases, treated hematologic cancer, and untreated solid cancers compared with the other groups.

Similarly, the IC₅₀ titers against the Delta variant were significantly lower in participants with solid organ transplants (median, 16.5; 95% CI, 8.5-68.1; P < .001), autoimmune diseases (median, 208.3; 95% CI, 164.4-373.5; P = .02), treated hematologic cancers (median, 255.4; 95% CI, 136.2-431.3; P = .02), and untreated solid cancers (median, 465.1; 95% CI, 406.4-529.3; P = .02) compared with healthy controls (median, 531.9; 95% CI, 483.1-584.4), untreated hematologic cancers (median, 490.4; 95% CI, 290.5-707.3), and treated solid cancers (median, 475.9; 95% CI, 401.2-551.2).

Figure 1. Percentages of Participants With Neutralizing Antibody (nAb) Responses at 1 Month and 3 Months After the Second Vaccine Dose

A Untreated hematologic cancers

B Untreated hematologic cancers

C Untreated solid cancers

D Treated solid cancers

Neutralizing antibody responses were measured against SARS-CoV-2 (the original, nonvariant SARS-CoV-2) and the different variants of concern. Data are expressed as IC₅₀ (half maximal inhibitory concentration) dilutions. Negative (gray bars) indicates IC₅₀ titers <50 dilutions; positive (colored bars) indicates IC₅₀ titers >50 dilutions. Values are median (SE, denoted by whiskers).
matologic cancers (median, 77.1; 95% CI, 36.1-143.3; \(P < .001\)) compared with healthy controls (median 197.1; 95% CI, 183.2-216.4), untreated solid cancers (median, 163.5; 95% CI, 142.4-185.1), treated solid cancers (median, 172.3; 95% CI, 134.3-188.5), and untreated hematologic cancers (median, 178.5; 95% CI, 129.2-253.1) (eTable 3 in the Supplement).

The IC\(_{50}\) titers against the Beta and Delta variants were about 3- to 4-fold lower compared with those against 2019-nCoV in all groups, with significant decreases (1.7- to 2.5-fold) in all the VOCs titers observed between month 1 and month 3 in all patient groups (with the exception of participants with solid organ transplants) (Figure 2; eFigure 4 in the Supplement). These responses were differentially associated with B-cell–depleting therapies and other classes of potent immunosuppressive agents, and there was a trend toward better humoral responses in participants younger than 65 years and in female participants (eTable 4 in the Supplement).

The IC\(_{50}\) titers against 2019-nCoV and the VOCs were consistently higher (3.0-4.0-fold) in the participants vaccinated with the mRNA-1273 vs BNT162b2 in all study groups at 1 month and 3 months after vaccination (Figure 3; eFigure 5 in the Supplement). To appreciate further the differences between the 2 mRNA vaccines, nAb responses were stratified on the basis of different IC\(_{50}\) titers. Of note, the percentage of individuals with IC\(_{50}\) titers lower than 50 (negative response) was higher in those vaccinated with BNT162b2 (eFigure 6 in the Supplement).

A fraction of participants (n = 661) with matched samples at 1 month, 3 months, and 6 months were analyzed for nAbs at 6 months after vaccination. The percentage of individuals with IC\(_{50}\) titers lower than 50 decreased substantially against the Beta and Delta variants (range, 22%-30%) at 6 months in the participants with solid organ transplants and autoimmune diseases (eFigure 7 in the Supplement). The decrease was more contained in the groups with hematologic cancers (median [SE], 39.2 [5.5%] for Beta and 41.8 [5.6%] for Delta), and solid cancers (44.8 [2.7%] for Beta and 51.9% [2.7%] for Delta) (Figure 4) and in the healthy controls (52.1 [4.2%] for Beta and 56.9 [4.1%] for Delta) (eFigure 7 in the Supplement).

We then determined the time to negative diagnostic levels of binding IgG anti-S antibodies (<5.19 U/mL) and nAbs (IC\(_{50}\) titers <50). A linear regression model using time as continu-
ous covariate (number of days after vaccination) was used for generating estimates. Among the different groups with matched data available at 1 month, 3 months, and 6 months after vaccination, 278 participants with solid cancers, 49 with hematologic cancers, and 101 healthy controls received BNT162b2, whereas 78 participants with solid cancers, 30 with hematologic cancers, and 43 healthy controls received mRNA-1273. Separate analysis between the 2 vaccines within the each group was performed only in participants with solid cancers and healthy controls because of the limited number of participants in the other groups, and no analysis was possible in participants with solid organ transplants and autoimmune diseases. The time to negative diagnostic level of binding IgG anti-S antibodies was estimated to be 1055 days in participants with solid cancers vaccinated with the mRNA-1273 vaccine and 578 days in those vaccinated with the BNT162b2 vaccine (eFigure 8 and eTable 5 in the Supplement).

The estimated time to negative diagnostic level of nAbs was much shorter compared with binding IgG antibodies (Figure 5; eFigure 8 in the Supplement); the times to IC\textsubscript{50} titers lower than 50 against 2019-nCoV were 286 and 226 days in participants with solid cancers vaccinated with mRNA-1273 and BNT162b2, respectively. The shortest estimated durations of response for nAbs were observed against the Beta variant (221 days with mRNA-1273 and 146 days with BNT162b2) and against the Delta variant (226 days with mRNA-1273 and 161 with BNT162b2). The estimated durations of responses for nAbs against the Alpha and Gamma variants were slightly shorter than against 2019-nCoV (Figure 5A; eFigure 8 in the Supplement). Overall, the estimates of the duration of binding IgG and neutralizing antibody responses in healthy controls were similar to those in participants with solid cancers (eFigure 9 in the Supplement). The estimated duration of both binding IgG and neutralizing antibodies was shorter in participants with hematologic cancers (Figure 5B; eFigure 10 in the Supplement).
ment), with 592 days for binding IgG anti-S antibodies, 208 days for nAbs against 2019-nCoV, and 113 and 127 days against Beta and Delta variants, respectively.

Of note, there was a 4.4- to 5.1-fold decay rate in nAbs between 1 month and 6 months for 2019-nCoV and the Alpha and Gamma variants and a 3.5-fold decay rate for the Beta and Delta variants and a 4.5- to 5.4-fold decay rate for binding IgG antibodies (eTable 3 in the Supplement). The type of vaccine and the underlying disease did not appear to have any influence on the decay rate.

Adverse event analyses are provided for 839 participants, collected at visits 2 and 3. Reactogenicity was generally mild or moderate with no severe or grade 4 symptoms reported or serious adverse events or deaths. As reported previously,7,8 the local reactogenicity was similar after the first and second dose, whereas systemic reactogenicity was more common and severe after the second dose. At visit 2, 82.5% of participants reported local and 67.5% reported systemic reactions after mRNA-1273 (eFigure 11A in the Supplement) vs 63.4% and 49.7%, respectively, after BNT162b2 (eFigure 11B in the Supplement). Overall, reactogenicity events were transient and resolved within a few days. Only 30 participants reported persistent reactions at visit 3, especially fatigue (11 participants), headache (7 participants), and persistent lymphadenopathy (2 participants). For local reactogenicity, more mRNA-1273 than BNT162b2 recipients reported pain (74.3% vs 59.2%), redness (14.6% vs 3.6%), and swelling (12.6% vs 2.8%) (eFigure 11A in the Supplement). Similarly, more mRNA-1273 recipients reported systemic reactions, including fatigue (36.9% vs 26.6%), fever (36.4% vs 9%), muscle pain (34.5% vs 13%), headache (28.6% vs 15.3%), joint pain (13.6% vs 7.1%), nausea (9.2% vs 4.9%), chills (6.8% vs 3.2%), and vomiting (3.4% vs 1.1%). No myocarditis or anaphylactic reactions were reported (eFigure 11B in the Supplement).

Discussion

In this comparative effectiveness study, we found that nAb IC50 titers were up to 4-fold lower against the Beta and Delta variants at 1 month after the second dose of vaccine, and we found a continuous waning of the nAbs over 6 months15,28,29,31 and a shorter duration of the responses against Beta and Delta variants vs 2019-nCoV.

Owing to the complexity of the pseudovirus and/or live virus neutralization assays, it has been proposed that binding IgG anti-S antibodies provide insights on the persistence of nAbs over time.37,38 However, in our study the estimated duration of the binding IgG anti-S antibodies was about 5- to 6-fold longer compared with nAbs depending on the type of vaccine in the different study groups. In contrast, the duration of nAbs against 2019-nCoV was estimated to be 8 to 9 months and only 3 to 6 months against the Beta and Delta variants. Therefore, binding IgG anti-S antibodies may not reflect the long-term persistence of nAbs against the VOCs.

Of note, nAb responses were of substantially greater magnitude and longer duration (7 to 9 weeks) after vaccination with the mRNA-1273 compared with the BNT162b2 vaccine in all study groups. The differences are likely associated with the higher concentration (greater than 3-fold) of mRNA-1273 compared with the BNT162b2 vaccine. Our results further support the recent findings of a study that included a small number of healthy donors (31 participants) that found greater responses with the mRNA-1273 vaccine.37

In contrast to immune checkpoint inhibitors, endocrine therapy, biologic disease-modifying antirheumatic drugs, or targeted therapies, treatments with anti-CD20 antibodies, Bruton tyrosine kinase inhibitors, Bcl-2 antagonists, anti-CD38 therapy, or antimetabolites have been associated with

Figure 4. Percentages of Participants With Neutralizing Antibody (nAb) Responses at 1 Month, 3 Months, and 6 Months After the Second Vaccine Dose

![Figure 4](https://example.com/figure4.png)

Untreated and treated hematologic cancers and solid cancers participants were combined for the analysis within each group. Negative (gray bars) indicates IC50 titers <50 dilutions; positive (colored bars) indicates IC50 titers >50 dilutions. Values are median (SE, denoted by whiskers). 2019-nCoV indicates the original, nonvariant SARS-CoV-2.

jamaoncology.com
impaired response to vaccination, as shown in previous studies.\textsuperscript{11-14,39} Our study suggests that the immunocompromised patients mostly affected are those with solid organ transplants, followed by patients with autoimmune diseases and hematologic cancers. Vaccine-induced immune responses in patients with solid cancers were similar overall to those in healthy participants, likely owing to a better function of the immune system and the lack of treatments with B-cell–depleting therapies or other potent immunosuppressive agents.

Strengths and Limitations

This study has several strengths. To our knowledge, it has the largest collection of immunocompromised individuals studied for response to COVID-19 vaccination and for the durability of the humoral response. It is also the first study, to our knowledge, to evaluate the vaccine-induced antibody responses against the original 2019-nCoV and the VOCs and presents the largest number of determinations of nAbs induced by vaccination (approximately 15,000). This large data set has been important for generating the estimates of the durability of the antibody responses against the different VOCs among the different groups of immunocompromised patients.

This study also has limitations. A main limitation of our study is that it is not suitable for determining the thresholds of nAbs conferring protection from infection because of its size and the length of the follow-up. Other limitations are the lack of assessment of the associations of the underlying disease and therapy with the vaccine-induced T-cell immunity as well as individual therapeutic agents with the vaccine-induced antibody responses.

Conclusions

The ImmunoVax comparative effectiveness study found substantial differences in waning of the nAb responses against 2019-nCoV vs the VOCs. The proportions of participants with positive nAbs and antibody titers were signifi-
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients

**CONFLICT OF INTEREST DISCLOSURES:** Dr Gottardo received personal fees from Takeda Consulting, and owning stocks from BioNTech, Ozone, and Modulus Therapeutics outside the submitted work. Dr Fenwick reported a pending patent (application No. EP202052981.1) for a neutralization assay used in this study. Dr Peters reported receiving personal fees (all to her institution) from advisory boards of Amgen, AstraZeneca, Bayer, BeGene, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, Foundation Medicine, Janssen, Merck Sharp & Dohme, Merci Serono, Novartis, Pharmamar, Phosplatin Therapeutics, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, and Takeda outside the submitted work. Dr Pantaleo reported having a patent pending (application No. EP202052981.1) for a neutralization assay used in this study. No other disclosures were reported.

**Funding/Support:** Dr Obeid received a grant from the Leenaards Foundation. Dr Pantaleo received a grant (No. 101005077) from the Corona Accelerated R&D in Europe project funded by the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 101005077. The JU receives support from the European Union’s Horizon 2020 research and innovation program, the European Federation of Pharmaceutical Industries Associations, the Bill and Melinda Gates Foundation, Global Health Drug Discovery Institute, and the University of Dundee and from Lausanne University Hospital, the Swiss Vaccine Research Institute, and Swiss National Science Foundation grants. The research is partially supported by the CoVICIS project (grant No. 101046041) funded by the European Union Horizon Europe program.

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** The authors thank the participants who volunteered for this study and the Vaccine and Immunology Center and the clinical diagnosis platform of the Service of Immunology and Allergy, Departments of Medicine and Laboratory Pathology, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland (Gottardo); Swiss Vaccine Research Institute, University of Lausanne Hospital, University of Lausanne, Switzerland (Pantaleo).

**Statistical analysis:** Obeid, Sufiottiti, Pellaton, Bouchaib, Cairoli, Salvadé, Molinari, Ri, Gottardo, Fenwick, Pascual, Duchosal, Peters, Pantaleo.

**Statistical software:** R.

**Neural network:** Deep learning.

**Machine learning:** Random forest.

**Supporting information:** Available at https://doi.org/10.1001/jamaoncol.2022.0446.

**References:**


resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 
